Investor Overview

Webcast ImageWebcast
Q4 2016 Dermira, Inc. Earnings Conference Call (Live)
02/28/17 at 4:30 p.m. ET
Q4 2016 Dermira, Inc. Earnings Conference Call
Tuesday, February 28, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases.
Featured Reports
There are currently no items available.
Recent Newsmore >
DateTitle
02/22/17Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
Management to Host Webcast and Conference Call on February 28, 2017 at 4:30 p.m. ET MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on February 28, 2... 
02/08/17Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. DERM, a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 1:30 p.m. ET (10:30 a.m. PT) on Wednesday, February ... 
01/19/17Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and MENLO PARK, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced key results from CIMPACT, a Phase 3, multi-center, placebo-controlled and active-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pe... 
01/06/17Dermira Provides Corporate Update
Treatment period for DRM04 ARIDO trial completed Phase 3 acne clinical program for olumacostat glasaretil initiated Topline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of 2017 Chief Commercial Officer appointed MENLO PARK, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... 
Stock Quotemore >
DERM (Common Stock)
Exchange :NASDAQ GS (US Dollar)
Price :$33.65
Change (%) : Stock is Up 0.45 (1.36%)
Volume :24,097
Data as of 02/27/17 10:39 a.m. ET
Minimum 20 minutes delay
Eventsmore >
Q4 2016 Dermira, Inc. Earnings Conference Call
Tuesday, February 28, 2017 4:30 p.m. ET

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Dermira, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Minimum 20 minutes delayed